COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Pharmacokinetics of AZD7295 Capsules

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01097408
Recruitment Status : Completed
First Posted : April 1, 2010
Last Update Posted : August 9, 2010
Information provided by:
Arrow Therapeutics

Brief Summary:
This is a pharmacokinetics (PK) and safety study of AZD7295 in healthy volunteers.

Condition or disease Intervention/treatment Phase
Healthy Drug: AZD7295 Drug: Placebo comparator Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 12 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: A Randomised, Double-Blind, Placebo-Controlled Study to Determine the Pharmacokinetics, Safety and Tolerability of AZD7295 Capsules in Healthy Volunteers
Study Start Date : March 2010
Actual Primary Completion Date : May 2010
Actual Study Completion Date : August 2010

Arm Intervention/treatment
Experimental: AZD7295 Drug: AZD7295
Up to 650mg AZD7295 capsules per dose. To be given 2 or 3 times daily for 5 days.

Placebo Comparator: Matched placebo Drug: Placebo comparator
Placebo capsules

Primary Outcome Measures :
  1. Pharmacokinetics of AZD7295 capsules [ Time Frame: 0-72h after each dose ]
    PK parameters of AZD7295 will be measured after single and repeated doses (AUC, Cmax, t1/2)

Secondary Outcome Measures :
  1. Safety and tolerability of AZD7295 capsules [ Time Frame: 0-72h after each dose ]
    Safety and tolerability of AZD7295 will be assessed after single and repeated doses (adverse events, ECGs, vital signs, safety laboratory tests)

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Healthy male or female volunteers, aged 18-65 years.

Exclusion Criteria:

  • Previous exposure to AZD7295, clinically relevant disease.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01097408

Layout table for location information
United Kingdom
Quotient Clinical Research
Nottingham, United Kingdom
Sponsors and Collaborators
Arrow Therapeutics
Layout table for investigator information
Principal Investigator: Jo Collier, Mb ChB Quotient Clinical Research
Layout table for additonal information
Responsible Party: Liz Clark, Arrow Therapeutics Identifier: NCT01097408    
Other Study ID Numbers: HCV689-105
First Posted: April 1, 2010    Key Record Dates
Last Update Posted: August 9, 2010
Last Verified: August 2010